NYSE:ZTS - Zoetis Stock Price, Forecast & News

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Zoetis declared a quarterly dividend on Friday, December 13th. Stockholders of record on Friday, January 17th will be paid a dividend of $0.20 per share on Tuesday, March 3rd. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.59%. The ex-dividend date of this dividend is Thursday, January 16th. This is an increase from Zoetis's previous quarterly dividend of $0.16. View Zoetis' Dividend History.

Zoetis declared that its Board of Directors has initiated a share repurchase plan on Wednesday, December 12th 2018, which authorizes the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 4.7% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's board believes its stock is undervalued.

Zoetis Inc (NYSE:ZTS) posted its quarterly earnings results on Thursday, November, 7th. The company reported $0.94 EPS for the quarter, beating the Zacks' consensus estimate of $0.88 by $0.06. The company earned $1.58 billion during the quarter, compared to the consensus estimate of $1.58 billion. Zoetis had a return on equity of 70.78% and a net margin of 23.76%. The company's revenue was up 7.0% compared to the same quarter last year. During the same period last year, the firm posted $0.83 EPS. View Zoetis' Earnings History.

Zoetis is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Zoetis.

Zoetis will be holding an earnings conference call on Thursday, February 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Zoetis updated its FY19 earnings guidance on Thursday, November, 7th. The company provided EPS guidance of $3.57-3.62 for the period, compared to the Thomson Reuters consensus estimate of $3.57. The company issued revenue guidance of $6.24 billion, compared to the consensus revenue estimate of prior $3.53-3.60.

15 analysts have issued 1 year target prices for Zoetis' shares. Their forecasts range from $105.00 to $145.00. On average, they expect Zoetis' share price to reach $129.54 in the next year. This suggests that the stock has a possible downside of 5.0%. View Analyst Price Targets for Zoetis.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 7 hold ratings, 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.

Media headlines about ZTS stock have trended extremely negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Zoetis earned a media sentiment score of -4.5 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Zoetis.

Zoetis saw a increase in short interest in January. As of January 15th, there was short interest totalling 5,940,000 shares, an increase of 21.0% from the December 31st total of 4,910,000 shares. Based on an average trading volume of 2,070,000 shares, the days-to-cover ratio is currently 2.9 days. Approximately 1.3% of the shares of the company are short sold. View Zoetis' Current Options Chain.

Some companies that are related to Zoetis include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Transocean (RIG) and Accenture (ACN).

Zoetis' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Milestone Resources Group Ltd (0.17%), New York State Teachers Retirement System (0.15%), State of Michigan Retirement System (0.12%), Artemis Investment Management LLP (0.10%), AMI Asset Management Corp (0.09%) and Strs Ohio (0.09%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Institutional Ownership Trends for Zoetis.

ZTS stock was sold by a variety of institutional investors in the last quarter, including Sonora Investment Management LLC, Artemis Investment Management LLP, Stack Financial Management Inc, Strs Ohio, Braun Stacey Associates Inc., Meag Munich Ergo Kapitalanlagegesellschaft MBH, DAVENPORT & Co LLC and AMI Asset Management Corp. Company insiders that have sold Zoetis company stock in the last year include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Insider Buying and Selling for Zoetis.

ZTS stock was acquired by a variety of institutional investors in the last quarter, including Milestone Resources Group Ltd, Johanson Financial Advisors Inc., TIAA FSB, James Investment Research Inc., Windward Capital Management Co. CA, Advisors Capital Management LLC, Chapman Investment Management LLC and Nisa Investment Advisors LLC. View Insider Buying and Selling for Zoetis.

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZTS stock can currently be purchased for approximately $136.31.

Zoetis has a market capitalization of $64.92 billion and generates $5.83 billion in revenue each year. The company earns $1.43 billion in net income (profit) each year or $3.13 on an earnings per share basis. Zoetis employs 10,000 workers across the globe.View Additional Information About Zoetis.

The official website for Zoetis is http://www.zoetis.com/.

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]